Gilead and Genesis partner for AI drug discovery

Gilead Sciences has partnered with Genesis Therapeutics to use its artificial intelligence–powered drug discovery technology, GEMS (Genesis Exploration of Molecular Space), to find new molecules for targets provided by Gilead. Gilead will pay Genesis $35 million for three targets. There could also be further payments if more targets are identified, along with milestone payments. Genesis previously collaborated with Genentech in a deal worth an undisclosed amount and with Eli Lilly and Company in a deal worth up to $670 million. It raised $200 million in a series B round in 2023.